MediWound Ltd. (MDWD) 股票分析

公司概述

MediWound Ltd. operates as a biopharmaceutical entity dedicated to the development, manufacturing, and commercialization of novel bio-therapeutic and non-surgical solutions designed specifically for tissue repair and regeneration across the United States, Germany, Italy, Spain, and international markets. The company is situated within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which typically requires substantial capital investment for research and development before achieving commercial profitability. As of the latest data, the company holds a market capitalization of $228.38M, reports trailing twelve-month revenue of $16.96M, and employs 121 individuals to execute its operational strategy. These financial metrics indicate that MediWound is a mid-sized market cap entity operating with a relatively small workforce, suggesting a lean organizational structure typical of early-to-mid stage biotechnology firms where revenue generation is still scaling relative to the significant R&D expenditures inherent to the sector.

财务健康

MediWound reported trailing twelve-month revenue of $16.96M alongside a net income of -$23,879,000 and an EBITDA of -$24,280,000, revealing a substantial gap between top-line sales and bottom-line profitability. This disparity highlights a cost structure where operating expenses, likely dominated by research, development, and general administrative costs, significantly exceed the gross profit generated from sales, resulting in a net loss that is more than 100% of the revenue base. The company generated free cash flow of -$15,578,875, indicating a net outflow of cash that reflects heavy investment in growth initiatives or ongoing operational burn rather than immediate liquidity generation from its current business model. In terms of profitability efficiency, the gross margin stands at 19.2%, suggesting that the cost of goods sold consumes a significant portion of revenue, while the operating margin of -417.8% and profit margin of -140.8% illustrate severe operating leverage issues and losses relative to sales. On the balance sheet, MediWound holds $53.14M in cash against $8.78M in debt, resulting in a debt-to-equity ratio of 20.11, which indicates a highly conservative capital structure with ample liquidity to cover liabilities. The current ratio of 2.33 further confirms strong short-term liquidity, as the company possesses more than twice the current assets needed to settle its current obligations without needing external financing. Return on equity is recorded at -63.9% and return on assets at -19.8%, metrics that reveal the company is currently utilizing shareholder capital and assets to generate negative returns, a common characteristic in biotechnology companies prioritizing future product launches over current profitability.

估值评估

The valuation metrics present a mixed picture for a loss-making biotechnology firm, with a trailing P/E ratio of N/A due to the lack of earnings and a forward P/E of -8.19, implying that analysts or the market anticipates a path to profitability or that current pricing discounts the stock heavily based on future expectations rather than historical performance. The price-to-book ratio is 5.23, indicating that the market values the company at over five times its net asset value, which suggests a significant premium assigned to its intangible assets such as intellectual property and pipeline potential rather than its tangible book value. Alternative valuation multiples like the price-to-sales ratio of 13.47 and an EV/EBITDA of -7.57 suggest that the stock is priced based on revenue multiples, a standard practice for pre-profitability biotechs, though the negative EV/EBITDA underscores the lack of current earnings power. The stock has traded between a 52-week high of $22.50 and a 52-week low of $14.77, and without a specific current share price provided in the facts, the trading range itself defines the volatility envelope within which the asset has moved over the past year. The beta value of 0.15 indicates that the stock exhibits very low volatility relative to the broader market, moving less than one-fifth as much as the S&P 500, which may reflect low liquidity or a niche market position rather than strong correlation with general market movements.

Growth & Income

MediWound experienced a year-over-year revenue growth of -68.0%, while earnings growth is listed as N/A due to the company's loss-making status, implying that the business is currently contracting or losing market share rather than expanding its top line. Since the company reports a net loss, it is impossible to compare earnings growth to revenue growth in a traditional sense, but the significant decline in revenue suggests that the company is in a challenging commercial phase or facing headwinds in its primary markets. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute any earnings to shareholders, which is consistent with its financial position of needing to retain all available cash to fund operations and R&D. The overall growth and income profile of MediWound is characterized by negative revenue expansion and a complete absence of dividend income, positioning the asset purely as a speculative play on future product success rather than a source of current yield or stable earnings growth.